Publications

Detailed Information

Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients

Cited 3 time in Web of Science Cited 3 time in Scopus
Authors

Ahn, Hyun Jin; Byun, Ja Min; Kim, Inho; Youk, Jeonghwan; Koh, Youngil; Shin, Dong-Yeop; Hong, Junshik; Yoon, Sung-Soo

Issue Date
2022-01
Publisher
KOREAN ACAD MEDICAL SCIENCES
Citation
JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.37 No.6, p. e48
Abstract
Poor graft function (PGF) is a serious, potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation. Eltrombopag has shown multilineage responses in patients with refractory severe aplastic anemia, supporting the idea that it may improve cytopenia in patients with PGF. This retrospective, single center analysis included 8 Korean patients receiving eltrombopag for PGF. Median interval between transplant and eltrombopag treatment was 73 days, and the median duration treatment was 3.5 weeks. With median maximum daily dose of 50 mg, the time to best response was 93 days. Median hemoglobin increased from 8.2 g/dL to 10.9 g/dL, platelet from 18.5 x 10(9)/L to 54 x 10(9)/L, and absolute neutrophil count from 1.25 x 10(9)/L to 3.32 x 10(9)/L. In conclusion, eltrombopag is a good option for PGF in Korean patients, even at a lower dose compared to western patients.
ISSN
1011-8934
URI
https://hdl.handle.net/10371/201654
DOI
https://doi.org/10.3346/jkms.2022.37.e48
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share